Abstract: Provided is an isolated antigen-binding protein, wherein the drug is used for the treatment of tumor, and the isolated antigen-binding protein comprises a PD-L1 binding moiety and an OX40 binding moiety, wherein: the OX40 binding moiety is capable of recognizing and/or binding amino acid residues G70 and/or F71 in a human OX40 extracellular domain; and the PD-L1 binding moiety is capable of recognizing and/or binding amino acid residues I54, Y56, E58, Q66 and/or R113 in an N-terminal IgV domain of human PD-L1. Further provided is a use of the isolated antigen-binding protein in preparing a drug, wherein the drug is used for the treatment of tumors.

Abstract: A human GLP-1 polypeptide variant, and a fusion protein or an immunoconjugate constructed by means of using the human GLP-1 polypeptide variant can be used for preventing, and/or treating metabolic diseases or conditions related to GLP-1.

Abstract: The present disclosure provides a dimer formed by two polypeptide chains, with each of the two polypeptide chains comprising an antibody Fc subunit, wherein the dimer comprises two or more immunoglobulin single variable domains (ISVDs), at least one of the ISVDs is specific for PD-L1, and at least one of the ISVDs is specific for CTLA4.

Abstract: The present disclosure provides a use of a dimer in the preparation of a medicament for treating a tumor in a subject in need thereof, and the dimer formed by two polypeptide chains, with each of the two polypeptide chains comprising an antibody Fc subunit, wherein the dimer comprises two or more immunoglobulin single variable domains (ISVDs), at least one of the ISVDs is specific for PD-L1, and at least one of the ISVDs is specific for CTLA4. The present disclosure also provides a method for treating a tumor in a subject in need thereof, wherein the subject is resistant to the therapy of an immune checkpoint inhibitor.

Abstract: The present disclosure provides a use of an immune checkpoint inhibitor in combination with a Her2 inhibitor in the preparation of a medicament for treating tumor in a subject in need thereof, and also provides a pharmaceutical composition comprising an effective amount of said immune checkpoint inhibitor and an effective amount of said Her2 inhibitor, and optionally a pharmaceutically acceptable excipient, as well as a use of the pharmaceutical composition in the preparation of a medicament for treating tumor in a subject in need thereof.

Abstract: Disclosed are a method for treating a tumor using a CTLA4-binding protein and a use thereof, wherein the CTLA4-binding protein specifically binds to CTLA4 and does not compete with a ligand of CTLA4 for binding to CTLA4. The CTLA4-binding protein described in the present application can effectively inhibit tumor growth.

Abstract: The present invention relates to the field of medical biology, and discloses a high-resolution crystal structure of a complex of PD-L1-blocking heavy-chain single-domain antibody KN035 binding with PD-L1, and the use of the crystal structure. The invention also relates to novel PD-L1 binding polypeptides or compounds developed based on the crystal structure and uses thereof.

Abstract: The present disclosure provides a dimer formed by two polypeptide chains, with each of the two polypeptide chains comprising an antibody Fc subunit, wherein the dimer comprises two or more immunoglobulin single variable domains (ISVDs), at least one of the ISVDs is specific for PD-L1, and at least one of the ISVDs is specific for CTLA4.

Abstract: The present disclosure provides a dimer formed by two polypeptide chains, with each of the two polypeptide chains comprising an antibody Fc subunit, wherein the dimer comprises two or more immunoglobulin single variable domains (ISVDs), at least one of the ISVDs is specific for PD-L1, and at least one of the ISVDs is specific for CTLA4.

Abstract: The present invention relates to the field of medical biology, and discloses a high-resolution crystal structure of a complex of PD-L1-blocking heavy-chain single-domain antibody KNO35 binding with PD-L1, and the use of the crystal structure. The invention also relates to novel PD-L1 binding polypeptides or compounds developed based on the crystal structure and uses thereof.